AbbVie Nears Almost $11 Billion Cash Deal for Apogee Therapeutics, FT Reports
2026-06-19 14:46:47
AbbVie Inc. is nearing a deal to buy Apogee Therapeutics Inc. for almost $11 billion in cash to bolster its anti-inflammatory portfolio, according to a Financial Times report. In the second sentence, according to Bloomberg, the report said the acquisition would expand AbbVie’s anti-inflammatory drug lineup.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
